A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs PT 112 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Phosplatin Therapeutics
- 07 Feb 2018 According to a Phosplatin Therapeutics media release, the company has enrolled the first cohort of patients in this trial.
- 20 Dec 2017 Status changed from not yet recruiting to recruiting.
- 02 Nov 2017 Planned initiation date changed from 31 Oct 2017 to 1 Dec 2017.